DAWN — Day One Biopharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $1.20bn
- $836.84m
- 23
- 18
- 78
- 34
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 14.9 | 13.8 | 72.7 | 147 | 206 |
Operating Profit | -14.9 | -13.8 | -72.7 | -147 | -206 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -17 | -43.8 | -72.8 | -142 | -189 |
Net Income After Taxes | -17 | -43.8 | -72.8 | -142 | -189 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -12.6 | -40.5 | -171 | -142 | -189 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -12.6 | -40.5 | -171 | -142 | -189 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.209 | -0.671 | -4.62 | -2.17 | -2.37 |
Dividends per Share |